Choline-stabilized orthosilicic acid,
does it really help with Improvement in skin elasticity and wrinkles, hair, and nails?
research showsSmall ch-OSA-specific RCTs reported positive signals in instrument surrogates such as skin roughness and hair cross-sectional area. However, the core trials were supported by the manufacturer, Bio Minerals, and these endpoints cannot be generalized to clinical appearance, treatment of hair loss, or improvement of nail disease. Without independent replication, the grade is C.
ads claimAdvertisements bundle “collagen generation,” “wrinkle reduction,” “skin elasticity,” “thicker and stronger hair,” and “stronger nails.” The actual trials measured instrument-based skin-surface values, hair-fiber mechanics, and subjective brittleness scores, which are not the same as clinical hair growth or wrinkle-treatment outcomes.
Useful facts when choosing a product
- The key skin trial used ch-OSA equivalent to 10 mg/day of elemental silicon for 20 weeks.
- The hair trial used 10 mg Si/day for nine months and measured hair tensile properties and cross-sectional area.
- ch-OSA and BioSil belong to Bio Minerals’ ingredient and trademark system, and study formulations may not be equivalent to generic silica products.
- No clear clinical-laboratory safety problem was reported in the short- and medium-term trials.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.choline-stabilized-orthosilicic-acid.UNK.skin-elasticity-and-wrinkles-hair-and-nails.improve.placeboUnknown > Choline-stabilized orthosilicic acid > Unknown > skin elasticity and wrinkles, hair, and nails > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Barel 2005 assigned 50 women with photodamaged facial skin to ch-OSA or placebo. After 20 weeks, there were between-group signals for changes in skin-roughness measures Rt and Rm and mechanical anisotropy, but the hair- and nail-brittleness VAS was reported as improvement from baseline within the ch-OSA group, leaving the placebo-comparative effect unclear. Wickett 2007 gave 48 women with fine hair 10 mg Si/day for nine months and reported increased hair cross-sectional area and less deterioration in elasticity and break properties. Both studies were supported by Bio Minerals.
Why this is classified as C (44)
The evidence consists of ch-OSA-specific studies supported by Bio Minerals and surrogate endpoints such as skin roughness and hair cross-sectional area. These cannot be generalized to clinical appearance, hair loss, or nail disease, and there is no independent replication, resulting in C with 44 points.
Counterpoint. Some objective skin-surface and hair-fiber measures showed a placebo-comparative signal, so this is not a case of no human efficacy evidence.
Rejudgment record. Reassessment (cross-check reflected) — Evidence is limited to ch-OSA-specific, Bio Minerals-supported surrogate endpoints such as skin roughness and hair cross-sectional area, which cannot be generalized to clinical appearance, hair loss, or nail disease, supporting C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Skin elasticity, roughness, and wrinkles | C | A 20-week manufacturer-supported RCT found signals in roughness and mechanical properties, but there was no clinical wrinkle endpoint or independent replication. |
| Hair thickness and strength | C | A nine-month ingredient-specific RCT found signals in cross-sectional area and tensile properties, but these were not clinical hair-growth endpoints. |
| Nail improvement | D | Nail brittleness relied on subjective scores and within-group change in a small trial, making placebo-comparative efficacy difficult to isolate. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Barel A et al. 2005 | Randomized, double-blind, placebo-controlled trial | 50 women with photodamaged skin, 20 weeks | Supported by Bio Minerals; included the ingredient developer as an author | Skin roughness, hydration, mechanical anisotropy, and hair/nail brittleness VAS | There were between-group signals for Rt and Rm roughness and mechanical properties; hair and nail VAS results were mainly within-group improvements. | Key |
| Wickett RR et al. 2007 | Randomized, double-blind, placebo-controlled trial | 48 women with fine hair, nine months | Supported by Bio Minerals | Hair cross-sectional area, elastic gradient, break load, and break stress | Cross-sectional area increased in the ch-OSA group and deterioration in some tensile properties was smaller than with placebo. | Key |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Choline-stabilized orthosilicic acid x improvement in skin elasticity and wrinkles, hair, and nails — Evidence Grade C·44. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/choline-orthosilicic-acid-skin-hair-nails/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.